IP Library Granted Patent US 11,103,586
Granted Patent B2
US 11,103,586 · App. 14/363,685 · Granted Aug 31, 2021

Exosomes for delivery of biotherapeutics

Inventors: Matthew Wood (Oxford, GB); Samira Lakhal-Littleton (Oxford, GB); Samir El Andaloussi (Oxford, GB)
Assignee: Oxford University Innovation Limited
A61K47/42A61K9/1271A61K35/36A61K39/00A61K39/44A61K47/58A61K47/62A61K47/6835A61K47/6901A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,103,586
App. No.
14/363,685
Granted
Aug 31, 2021
Kind
B2
Abstract

The present invention relates to exosomes, loaded with biotherapeutic protein and/or peptide and methods of producing them and to the use of such exosomes for delivering protein and/or peptide in vivo, in particular the use of such exosomes in methods of therapy.

Claims (8)

1. A composition comprising a therapeutic delivery exosome and a pharmaceutically acceptable carrier, wherein the exosome is loaded with exogenous recombinant therapeutic monoclonal antibodies or antigen binding fragments thereof, and wherein the antibodies or antigen binding fragments thereof are encapsulated inside the exosome and do not elicit an immune response when inside the exosome.

2. A composition according to claim 1 , wherein the exogenous recombinant therapeutic monoclonal antibodies or antigen binding fragments thereof are for use in a method of treatment of the human or animal body by therapy.

3. A composition according to claim 2 , wherein the exogenous recombinant therapeutic monoclonal antibodies or antigen binding fragments thereof are for use in the treatment of cancer, autoimmune conditions, cardiovascular disease, haemophilia, sepsis, stroke, muscular dystrophy, muscular degeneration, Alzheimer's disease or organ or cell transplant rejection.

4. A composition according to claim 1 , wherein said exosome comprises a targeting moiety expressed on the surface of the exosome.

5. A composition according to claim 4 , wherein the targeting moiety comprises a peptide which binds to a moiety present on the cell to be targeted.

6. A composition according to claim 5 , wherein the exosome comprises an exosomal transmembrane protein which has been modified to incorporate the peptide targeting moiety.

7. A composition according to claim 6 , wherein the exosomal transmembrane protein is selected from Lamp-1, Lamp-2, CD13, CD86, Flotillin, or Syntaxin-3.

8. A composition according to claim 7 , wherein the exosomal transmembrane protein is Lamp-2b.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2021
From: EL ANDALOUSSI, SAMIR
To: OXFORD UNIVERSITY INNOVATION LIMITED
Reel/Frame 056499/0486 →
CHANGE OF NAME Recorded Aug 2, 2016
From: ISIS INNOVATION LIMITED
To: OXFORD UNIVERSITY INNOVATION LIMITED
Reel/Frame 039550/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2014
From: WOOD, MATTHEW; LAKHAL-LITTLETON, SAMIRA
To: ISIS INNOVATION LIMITED
Reel/Frame 033252/0182 →
Cited By (4)
US 12,319,938 US 12,351,814 US 12,351,815 US 12,404,525